Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
January 04, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update on the clinical development of its oral first-in-class...
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
March 13, 2023 08:00 ET
|
Aridis Pharmaceuticals, Inc.
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif.,...
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
December 05, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease
July 10, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 10, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will present a Montelukast...
IntelGenx Announces Addition of Peterborough’s Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site
June 19, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, June 19, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, the Kawartha Centre has...
IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Completes 26-Week Treatment
June 10, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, June 10, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it has added a new Ottawa site...
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site
February 14, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that, subject to final research...
IntelGenx Provides Update on Phase 2a Montelukast VersaFilm™ Clinical Trial
January 23, 2019 08:00 ET
|
IntelGenx Technologies Corp.
Eight Alzheimer’s Disease Patients Randomized to Date with Two Additional Sites Expected SAINT LAURENT, Quebec, Jan. 23, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...
IntelGenx Begins Montelukast VersaFilm™ Dosing in Patients with Mild to Moderate Alzheimer’s Disease in Phase 2a Study
November 27, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 27, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient dosing has commenced in the Phase 2a...
Patient Recruitment to Commence in IntelGenx’s Phase 2a Montelukast VersaFilm™ Trial in Mild to Moderate Alzheimer’s Disease
September 25, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 25, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient recruitment will commence for the...